IRIS UniCatt

Danese, Silvio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.240
NA - Nord America 3.260
AS - Asia 2.603
SA - Sud America 460
AF - Africa 62
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.635
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.175
IT - Italia 1.594
SG - Singapore 1.210
DE - Germania 1.194
CN - Cina 628
SE - Svezia 390
BR - Brasile 362
UA - Ucraina 295
FR - Francia 220
VN - Vietnam 207
GB - Regno Unito 133
IE - Irlanda 113
JP - Giappone 91
IN - India 89
ID - Indonesia 78
FI - Finlandia 74
TR - Turchia 63
RU - Federazione Russa 61
BD - Bangladesh 56
CA - Canada 46
HK - Hong Kong 42
AR - Argentina 36
NL - Olanda 34
MX - Messico 25
IQ - Iraq 24
ZA - Sudafrica 24
PL - Polonia 22
KR - Corea 19
ES - Italia 17
PK - Pakistan 15
RO - Romania 14
EC - Ecuador 13
AT - Austria 12
BE - Belgio 11
IR - Iran 11
VE - Venezuela 11
CO - Colombia 10
JO - Giordania 10
SA - Arabia Saudita 9
UZ - Uzbekistan 9
PY - Paraguay 8
CH - Svizzera 7
PH - Filippine 7
PT - Portogallo 7
UY - Uruguay 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
AL - Albania 5
AU - Australia 5
CZ - Repubblica Ceca 5
EG - Egitto 5
GR - Grecia 5
LT - Lituania 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
EU - Europa 4
HR - Croazia 4
KE - Kenya 4
MA - Marocco 4
PE - Perù 4
TN - Tunisia 4
AZ - Azerbaigian 3
BZ - Belize 3
CI - Costa d'Avorio 3
ET - Etiopia 3
IL - Israele 3
KG - Kirghizistan 3
LB - Libano 3
ME - Montenegro 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
CG - Congo 2
EE - Estonia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MD - Moldavia 2
MY - Malesia 2
OM - Oman 2
PS - Palestinian Territory 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BO - Bolivia 1
CM - Camerun 1
DK - Danimarca 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
Totale 10.625
Salva come PNG Salva come JPEG
Città #
Singapore 693
Chandler 418
Ashburn 351
San Jose 303
Milan 172
Jacksonville 164
Rome 144
San Mateo 132
Dublin 111
Beijing 91
New York 85
Nanjing 80
Nürnberg 78
Tokyo 78
Wilmington 72
Lauterbourg 71
Jakarta 67
Hefei 66
Los Angeles 66
Ann Arbor 63
Ho Chi Minh City 58
Boston 57
Dearborn 57
Hanoi 54
Munich 51
Princeton 46
Izmir 43
Frankfurt am Main 41
Hong Kong 40
Dallas 34
The Dalles 34
Woodbridge 32
Houston 31
Nanchang 31
Redwood City 31
Moscow 30
Palermo 30
Turin 29
São Paulo 28
Bari 26
Seattle 25
Bremen 22
Cattolica 22
Detroit 22
Hebei 20
Marseille 20
Mountain View 20
Bologna 19
Buffalo 19
Florence 19
Boardman 18
Guangzhou 17
Lawrence 17
Naples 17
Shenyang 17
Changsha 16
Santa Clara 16
Brooklyn 15
Council Bluffs 15
Fairfield 15
Kunming 15
Pune 15
Toronto 15
University Park 15
Da Nang 14
Chicago 13
Genoa 13
Hangzhou 13
Kent 13
Zhengzhou 13
Catania 12
Jiaxing 12
Johannesburg 12
Tianjin 12
Baghdad 11
Belo Horizonte 11
Norwalk 11
Rio de Janeiro 11
Warsaw 11
Amman 10
Castignano 10
Manchester 10
Montreal 10
Nuremberg 10
Orem 10
Seoul 10
Treviso 10
Udine 10
Vienna 10
Andover 9
Augusta 9
Brasília 9
Brussels 9
Denver 9
Helsinki 9
Paris 9
Chennai 8
Jinan 8
Leawood 8
San Francisco 8
Totale 4.896
Salva come PNG Salva come JPEG
Nome #
Ruolo dei fattori psicologici nelle malattie infiammatorie croniche intestinali 1.764
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 368
Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. 250
-High prevalence of celiac disease in patients with lactose intolerance 230
Early atherosclerosis in patients with inflammatory bowel disease. 212
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 212
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 210
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 198
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 190
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 189
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. 178
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 174
Pathophysiology, diagnosis and treatment of non-erosive reflux disease (NERD) 173
Association between K469E allele of intercellular adhesion molecule 1 gene and inflammatory bowel disease in different populations. 170
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 169
-Extraintestinal manifestations in inflammatory Bowel disease. 151
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 148
Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease 147
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 146
Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication 142
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 142
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 141
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? 140
A novel pathogenic role for microvasculature in inflammatory bowel disease. 138
Biological therapies for inflammatory bowel disease: research drives clinics. 131
Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events 129
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 128
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 126
Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients 126
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing 125
Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine 125
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer. 121
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 119
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial 115
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 115
-Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation 114
Gender, chronic infection and myocardial infarction 114
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease 114
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 112
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 109
Severe liver injury associated with zafirlukast 106
Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery 106
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. 105
Promoting psycho-social wellbeing for engaging inflammatory bowel disease patients in their care: an Italian consensus statement 105
Elevated homocysteine levels in patients with Raynaud's syndrome 99
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 98
Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international study 97
Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment. 95
ag) Antibody to alpha4beta7 integrin for ulcerative colitis. 94
ag) CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems. 92
Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases 92
Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience 91
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease 90
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease 89
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study 88
Folate in gastrointestinal health and disease 87
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. 87
A) CD40L-positive platelets induce CD40L expression de novo in endothelial cells: adding a loop to microvascular inflammation. 84
Inflammatory bowel diseases and psychological issues: A new approach for a systematic analysis of the academic debate 84
Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials 83
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease 82
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality 82
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis 78
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 77
Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study 76
Unveiling role of sphingosine-1-phosphate receptor 2 as a brake of epithelial stem cell proliferation and a tumor suppressor in colorectal cancer 73
Genetic and nutritional predictors of hyperhomocysteinemia in inflammatory bowel disease 73
Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease 71
Thrombotic complications in inflammatory bowel disease: a multifactorial etiology 70
ag) Chemokines in inflammatory bowel disease. 68
High prevalence of Helicobacter priori type I virulent strains in patients with systemic sclerosis [6] (multiple letters) 67
-Antibody to alpha4beta7 integrin for ulcerative colitis 63
Assessment of prothrombotic risk in patients with Behçet's disease should include homocysteine plasma levels 53
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference 29
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY) 15
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) 3
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 1
Totale 10.758
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.080
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.080
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 0 0 28
2021/2022689 48 66 19 49 32 18 17 127 27 38 113 135
2022/20231.309 146 164 101 202 95 156 66 117 154 26 42 40
2023/2024771 41 190 48 46 62 78 50 32 22 47 69 86
2024/20251.274 46 38 129 52 125 50 70 75 158 121 238 172
2025/20263.483 507 115 218 411 617 146 533 200 260 234 151 91
Totale 10.758